Prelude Therapeutics Incorporated (PRLD) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts PRLD Hot Sheet
Join SI Premium – FREE
Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.46), $0.04 worse than the analyst estimate of ($0.42).
For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Full Circle Lithium closes $5.14M private placement
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
